Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of DHE Inhalation Powder, IV, and Nasal Spray in Healthy Adults
NCT07226362Phase 1Completed
- Sponsor
- Aspeya
- Start
- Jun 2025
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dihydroergotamine in migraine (4 arms), sponsored by Aspeya. Primary endpoints: Area under the curve from time zero to last measurable concentration at 48 hours, Area under the curve from time zero to infinity at 48 hours and 1 more. Started Jun 2025; status: completed.
02
Drugs
dihydroergotamine
03
Conditions
migraine
Beyond the preview
Go deeper on NCT07226362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07226362.